Breast Cancer Drug Aromasin May Be Option for Some Premenopausal Women

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

It produced lower 5-year recurrence rates compared to tamoxifen, but didn't boost overall survival, study finds



You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.